Germany Pneumococcal Vaccines Market Insights Forecasts to 2033

• The Germany Pneumococcal Vaccines Market Size was valued at USD 190.5 Million in 2023.
• The Market is Growing at a CAGR of 2.36% from 2023 to 2033
• The Germany Pneumococcal Vaccines Market Size is Expected to Reach USD 240.5 Million by 2033

The Germany Pneumococcal Vaccines Market is anticipated to exceed USD 240.5 Million by 2033, growing at a CAGR of 2.36% from 2023 to 2033. The growing prevalence of pneumonia and a strong pipeline for pneumococcal vaccines are driving the growth of the pneumococcal vaccines market in Germany.     

Market Overview

Pneumococcal vaccines are a pharmacologic compound that improves a person’s immunity to a pneumococcal disease, which is any type of illness caused by Streptococcus pneumoniae bacteria. Pneumococcal diseases refers to any illness caused by pneumococcal bacteria. Besides pneumonia, pneumococcal bacteria can also cause ear infections, sinus infections, meningitis, and bacteremia. There are two kinds of pneumococcal vaccines viz. pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) and pneumococcal polysaccharide vaccine (PPSV23). To prevent pneumococcal diseases, the German Standing Committee on Vaccination Recommendations (Ständige Impfkommission, STIKO) recommends standard vaccination for all persons older than 60. Vaccination based on a particular indication, and independent of age, is recommended for persons with an increased health risk.  CDC recommends pneumococcal conjugate vaccines for children younger than 5 years old while. PCV vaccines are also recommended for adults who never received a PCV and are aged 65 years or older and ages 19 to 64 years old with certain risk conditions. Pneumococcal polysaccharide vaccine (PPSV23) is used followed by PCV15 vaccination. As estimated there are about 740,000 pneumonia patients in the country each year. Despite advanced care facilities, an estimated 12% of patients do not survive which has intensified the market demand for pneumococcal vaccines.        

Report Coverage

This research report categorizes the market for the Germany pneumococcal vaccines market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the pneumococcal vaccines market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the pneumococcal vaccines market.

Driving Factors

The rising prevalence of pneumonia accounts for 740,000 pneumonia-suffering patients in the country each year. Further, the introduction of new types of vaccines. For instance, V114, a potential pipeline candidate from Merck 7 Co., Inc., is currently in phase 3 of clinical trials and is a 15-valent pneumococcal conjugate vaccine. Further, the increasing adoption of advanced pneumococcal polysaccharide vaccines owing to rising cases of pneumonia is driving the Germany pneumococcal vaccines market.

Restraining Factors

The longer manufacturing procedure of pneumococcal vaccines and the high cost of pneumococcal vaccine development are restraining the Germany pneumococcal vaccines market.

Market Segmentation

The German Pneumococcal Vaccines Market share is classified into product type and end user.

• The PCV13 segment dominated the market with the largest market share in 2023.

The Germany pneumococcal vaccines market is segmented by product type into PCV10, PCV13, and PPSV23. Among these, the PCV13 segment dominated the market with the largest market share in 2023. PCV13 vaccines are provided by government agencies at economic cost owing to their established clinical efficacy and reduction in the overall cost of the treatment.   

• The clinics segment is expected to hold the largest market share during the forecast period.

The Germany pneumococcal vaccines market is segmented by end user into hospitals, clinics, and others. Among these, the clinics segment is expected to hold a significant share of the Germany pneumococcal vaccines market during the forecast period. The high preference of patients towards clinics. It was estimated that 90% of child immunization for pneumococcal vaccines is performed at the Physician’s office according to the STIKO (Standing Committee on Vaccination at the Robert Koch Institute).

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US pneumococcal vaccines market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Merck & Co. Inc.
• Pfizer
• GlaxoSmithKline plc
• Sanofi
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In December 2023, Merck gets FDA decision date for new pneumococcal vaccines referred to as V116. If approved, V116 is expected to be added to Merck’s pneumococcal vaccine franchise and compete against Pfizer’s leading Prevnar 20 shot.

Market Segment

This study forecasts revenue at Germany, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Germany Pneumococcal Vaccines Market based on the below-mentioned segments

Germany Pneumococcal Vaccines Market, By Product Type

• PCV10
• PCV13
• PPSV23

Germany Pneumococcal Vaccines Market, By End User

• Hospitals
• Clinics
• Others